These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 36384351)

  • 1. Vaccines on demand, part II: future reality.
    Geall AJ; Kis Z; Ulmer JB
    Expert Opin Drug Discov; 2023 Feb; 18(2):119-127. PubMed ID: 36384351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines' New Era-RNA Vaccine.
    Zhou W; Jiang L; Liao S; Wu F; Yang G; Hou L; Liu L; Pan X; Jia W; Zhang Y
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research progress on the quality control of mRNA vaccines.
    Hu C; Bai Y; Liu J; Wang Y; He Q; Zhang X; Cheng F; Xu M; Mao Q; Liang Z
    Expert Rev Vaccines; 2024; 23(1):570-583. PubMed ID: 38733272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA.
    Zimmermann L; Erbar S
    Methods Mol Biol; 2024; 2786():135-144. PubMed ID: 38814392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing mRNA technologies for therapies and vaccines: An African context.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Front Immunol; 2022; 13():1018961. PubMed ID: 36353641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection.
    Xue VW; Wong SCC; Li B; Cho WCS
    Expert Opin Drug Discov; 2023 Jul; 18(7):769-780. PubMed ID: 37237360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-amplifying RNA vaccines for infectious diseases.
    Bloom K; van den Berg F; Arbuthnot P
    Gene Ther; 2021 Apr; 28(3-4):117-129. PubMed ID: 33093657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
    Granados-Riveron JT; Aquino-Jarquin G
    Biomed Pharmacother; 2021 Oct; 142():111953. PubMed ID: 34343897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.
    Wei J; Hui AM
    Cancer Treat Rev; 2022 Jun; 107():102405. PubMed ID: 35576777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
    Chaudhary N; Weissman D; Whitehead KA
    Nat Rev Drug Discov; 2021 Nov; 20(11):817-838. PubMed ID: 34433919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.
    Ye Z; Harmon J; Ni W; Li Y; Wich D; Xu Q
    ACS Nano; 2023 Aug; 17(16):15231-15253. PubMed ID: 37535899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
    Jin L; Han Z; Zhao P; Sun K
    Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making COVID-19 mRNA vaccines accessible: challenges resolved.
    Niazi SK
    Expert Rev Vaccines; 2022 Sep; 21(9):1163-1176. PubMed ID: 35695469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
    Milane L; Amiji M
    Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.